Skip to main content
Premium Trial:

Request an Annual Quote

InteRNA Closes Financing Round

Premium

InteRNA Technologies said this week that it has secured an undisclosed amount of equity financing, which it said would be used to develop its preclinical microRNA-based melanoma treatment.

The drug candidate is a mimic of miR-3157, which has been shown in vitro to inhibit proliferation and induce apoptosis in tumor cells. Last year, InteRNA CEO Roel Schaapveld told Gene Silencing News that the company aims to move the agent into human testing by the end of 2013 (GSN 10/25/2012).

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.